ARTICLE | Clinical News
Tigecycline regulatory update
November 11, 2013 8:00 AM UTC
Stem Cell Therapeutics said FDA granted Orphan Drug designation to tigecycline to treat acute myelogenous leukemia (AML). The glycylcycline antibiotic is in a Phase I trial in patients with relapsed o...